COSTEM Program

Thursday, 26.10.2017 Hall A	
18:00-19:00	*Industry supported* **Pre-Congress Workshop**
19:00	***Welcome Reception***

Friday, 27.10.2017			
08:30-10:00	**Hall A** **Plenary Session 1: Cellular Therapy vs. Transplantation** **Moderators: Nicolaus Kröger**, Germany & **Arnon Nagler**, Israel		
08:30-08:35	Introduction: *Moderators*		
08:35-09:15 08:35-08:50 08:50-09:05 09:05-09:15	*Controversy*: Can CAR-T cell therapy replace allogeneic SCT in ALL? Yes: **Michael Pulsipher**, USA No: **David Marks**, UK Discussion		
09:15-10:00 09:15-09:30 09:30-09:45 09:45-10:00	*Controversy*: Can haploidentical SCT replace MUD transplantation? Yes: **Andrea Bacigalupo**, Italy No: **Arnon Nagler**, Israel Discussion		
10:00-10:30	***Coffee Break, Poster Viewing and Visit Exhibition***		
10:30-12:00	**Hall A** **Session 2: Haploidentical Stem Cell Transplantation**	**10:30-12:00**	**Hall B** **Session 3: Myelodysplastic Syndrome**
10:30-11:15 10:30-10:45 10:45-11:00 11:00-11:15	*Controversy:* Optimal GvHD prophylaxis for T-cell repleted haploidentical SCT Moderator: **Annalisa Ruggeri**, France Pro post Cy: **Kavita Raj**, UK Pro ATG: **Xiangyu Zhao**, China Discussion	**10: 30-11:15** 10:30-10:45 10:45-11:00 11:00-11:15	*Controversy:* Should all lower-risk MDS patients be transplanted upfront? Moderator: **Nicolaus Kröger**, Germany Yes: **Ibrahim Yakoub-Agha**, France No: **Pierre Fenaux**, France Discussion
11:15-12:00 11:15-11:30 11:30-11:45 11:45-12:00	*Controversy:* Is bone marrow the preferred graft source for post cyclophosphamide-based haploidentical SCT? Moderator **Andrea Bacigalupo**, Italy Yes: **Stefan Ciurea**, USA No: **Annalisa Ruggeri**, France Discussion	**11:15-12:00** 11:15-11:30 11:30-11:45 11:45-12:00	*Controversy:* Should MDS patients receive 5-azacytidine for bridging to allogeneic SCT? Moderator: **Pierre Fenaux**, France Yes: **Marie Robin**, France No: **Avichai Shimoni**, Israel Discussion
12:00-12:45	***Lunch, Poster Viewing and Visit Exhibition***		
12:45-13:45	*Industry-supported* **Satellite Symposium – Hall A**		
13:45-14:00	***Short Break***		
14:00-15:30	**Hall A** **Session 4: GvHD Prevention**	**14:00-15:30**	**Hall B** **Session 5: Acute Lymphoblastic Leukemia**
14:00-14:45	*Controversy:* Do we need ATG for GvHD prophylaxis in unrelated transplants?	**14:00-14:45**	*Controversy:* Can allogeneic SCT in ALL be replaced by antibody therapy? Moderator: **Dieter Hoelzer**, Germany

	Moderator: **Paul Martin**, USA	14:00-14:15	Yes: **Arnon Nagler**, Israel
14:00-14:15	Yes: **Jürgen Finke**, Germany	14:15-14:30	No: **Peter Bader**, Germany
14:15-14:30	No: **Robert J. Soiffer**, USA	14:30-14:45	Discussion
14:30-14:45	Discussion		
14:45-15:30	*Controversy:* Microbiota modification by antibiotics or (living) probiotics	**14:45-15:30**	*Controversy:* Can Ph+ ALL be cured without allogeneic SCT?
	Moderator: **Robert J. Soiffer**, USA		Moderator: **Arnon Nagler**, Israel
14:45-15:00	Yes: **Ernst Holler**, Germany	14:45-15:00	Yes: **Sabina Chiaretti**, Italy
15:00-15:15	No: **Robert Zeiser**, Germany	15:00-15:15	No: **Dieter Hoelzer**, Germany
15:15-15:30	Discussion	15:15-15:30	Discussion
15:30-16:00	***Coffee Break, Poster Viewing and Visit Exhibition***		
16:00-17:30	**Hall A**	**16:00-17:30**	**Hall B**
	Session 6: GvHD Treatment		**Session 7: Acute Myeloid Leukemia**
16:00-17:30	*Controversy:* Did we improve in treatment of steroid-resistant GvHD?	**16:00-16:45**	*Controversy:* Is MAC the standard for AML patients?
	Moderator: **Ernst Holler**, Germany		Moderator: **Jan Cornelissen**, The Netherlands
16:00-16:15	Yes, by prediction (biomarker): **James Ferrara**, USA	16:00-16:15	Yes: **Bart Lee Scott**, USA
16:15-16:30	Yes, by JAK-inhibitors and antibodies: **Takanori Teshima**, Japan	16:15-16:30	No: **Charles Craddock**, UK
16:30-16:45	Yes, by MSC: **Maija Itälä-Remes**, Finland	16:30-16:45	Discussion
16:45-17:00	No, Not really: **Paul Martin**, USA		
17:00-17:30	Discussion		
		16:45-17:30	*Controversy:* Optimal method to monitor MRD in AML pre and post-transplant
			Moderator: **Charles Craddock**, UK
		16:45-17:00	FACS: **Roland B. Walter**, USA
		17:00-17:15	NGS: **Torsten Haferlach**, Germany
		17:15-17:30	Discussion
		17:30-17:45	*Short Break*
		17:45-18:45	*Industry-supported* **Post-Program Workshop**

Saturday, 28.10.2017			
08:30-10:00	**Hall A** **Session 8: Hodgkin and Non Hodgkin (NHL)**	**08:30-10:00**	**Hall B** **Session 9: Multiple Myeloma**
08:30-09:15 08:30-08:45 08:45-09:00 09:00-09:15	*Controversy:* Haplo SCT or checkpoint inhibitor for relapsed Hodgkin lymphoma? Moderator: **Michael R. Bishop**, USA Pro haplo: **Jorge Gayoso**, Spain Pro checkpoint inhibitor: **Meirav Kedmi**, Israel Discussion	**08:30-09:15** 08:30-08:45 08:45-09:00 09:00-09:15	*Controversy:* Should maintenance after autograft be given until progression? Moderator: **Sergio A. Giralt**, USA Yes: **Nicolaus Kröger**, Germany No: **Mohamad Mohty**, France Discussion
09:15-10:00 09:15-09:30 09:30-09:45 09:45-10:00	*Controversy:* Can CAR-T cell therapy replace autologous SCT in relapsed diffuse large B-cell lymphoma? Moderator: **Meirav Kedmi**, Israel Yes: **Michael R. Bishop**, USA No: **Bertram Glass**, Germany Discussion	**09:15-10:00** 09:15-09:30 09:30-09:45 09:45-10:00	*Controversy:* Tandem autologous is the standard for newly diagnosed younger myeloma patients Moderator: **Mohamad Mohty**, France Yes: **Michele Cavo**, Italy No: **Sergio A. Giralt**, USA Discussion
10:00-10:30	***Coffee Break, Poster Viewing and Visit Exhibition***		
10:30-12:00	**Hall A** **Session 10: Non Hodgkin Lymphoma**	**10:30-12:00**	**Hall B** **Session 11: Myeloproliferative Neoplasia and ATG**
10:30-11:15 10:30-10:45 10:45-11:00 11:00-11:15	*Controversy:* Is there still a place for allogeneic SCT for CLL in 2017? Moderator: **Silvia Montoto**, UK Yes: **Johannes Schetelig**, Germany No: **Ohad Benjamini**, Israel Discussion	**10:30-11:15** 10:30-10:45 10:45-11:00 11:00-11:15	*Controversy:* Can JAK-inhibition replace allogeneic SCT? Moderator: **Nicolaus Kröger**, Germany Yes: **Haifa Kathrin Al-Ali**, Germany No: **Vikas Gupta**, Canada Discussion
11:15-12:00 11:15-11:30 11:30-11:45 11:45-12:00	*Controversy:* Is there still a role for autologous SCT in follicular lymphoma? Moderator: **Bertram Glass**, Germany Yes: **Silvia Montoto**, UK No: **Kai Hübel**, Germany Discussion	**11:15-12:00** 11:15-11:30 11:30-11:45 11:45-12:00	*Controversy:* Is ATG dosing according lymphocyte count the new standard? Moderator: **Francis Ayuk**, Germany Yes: **Jaap Jan Boelens**, The Netherlands No: **Jan Storek**, Canada Discussion
12:00-12:45	***Lunch, Poster Viewing and Visit Exhibition***		
12:45-13:45	*Industry-supported* **Satellite Symposium – Hall A**		
13:45-14:00	***Short Break***		
14:00-15:30	**Hall A** **Session 12: Cord Blood Transplantation**	**14:00-15:30**	**Hall B** **Session 13: Bone Marrow Failure Syndrome**
14:00-14:45 14:00-14:15 14:15-14:30 14:30-14:45	*Controversy:* Is cord blood the best graft source for MRD + disease? Moderator: **Jaime Sanz Caballer**, Spain Yes: **Vanderson Rocha**, France No: **Jan Cornelissen**, The Netherlands Discussion	**14:00-14:45** 14:00-14:15 14:15-14:30 14:30-14:45	*Controversy:* Is upfront unrelated stem cell transplantation in severe Aplastic Anemia a new standard? Moderator: **Judith Marsh**, UK Yes: **Carlo Dufour**, Italy No: **Régis Peffault de Latour**, France Discussion
14:45-15:30 14:45-15:00	*Controversy:* Are two units of cord blood out? Moderator: **Vanderson Rocha**, France Yes: **Jaime Sanz Caballer**, Spain	**14:45-15:30**	*Controversy:* Mono- or polyclonal antibodies for allogeneic SCT in aplastic anemia? Moderator: **Carlo Dufour**, Italy

15:00-15:15 15:15-15:30	No: **Karen K. Ballen**, USA Discussion	14:45-15:00 15:00-15:15 15:15-15:30	Pro Campath: **Judith Marsh**, UK Pro ATG: **Hans-Jochem Kolb**, Germany Discussion
15:30-16:00	***Coffee Break, Poster Viewing and Visit Exhibition***		
16:00-17:30	**Hall A** **Session 14: Prevention of Relapse and Complications**	**16:00-17:30**	**Hall B** **Session 15: Conditioning Regimen**
16:00-16:45 16:00-16:15 16:15-16:30 16:30-16:45	*Controversy:* Can the existing VOD criteria properly cover the differences between adult and pediatric patients? Moderator: **Robert Gale**, UK Yes: **Ibrahim Yakoub-Agha**, France No: **Selim Corbacioglu**, Germany Discussion	**16:00-16:45** 16:00-16:15 16:15-16:30 16:30-16:45	*Controversy:* Is there still a role for cyclophosphamide as part of the conditioning regimen in 2017 (no post Cy!)? Moderator: **Martin Bornhäuser**, Germany Yes: **Jakob Passweg**, Switzerland No: **Alessandro Rambaldi**, Italy Discussion
16:45-17:30 16:45-17:00 17:00-17:15 17:15-17:30	*Controversy:* Is there a role of hypomethylating agents to prevent relapse? Moderator: **Alessandro Rambaldi**, Italy Yes: **Marcos de Lima**, USA No: **Robert Gale**, UK Discussion	**16:45-17:30** 16:45-17:00 17:00-17:15 17:15-17:30	*Controversy:* Is there a role for 2 Gy TBI conditioning in 2017? Moderator: **Jakob Passweg**, Switzerland Yes: **Dietger Niederwieser**, Germany No: **Martin Bornhäuser**, Germany Discussion
17:30-18:30	***Poster Walk and Awards***		

Sunday, 29.10.2017 Hall B	
08:30-10:00	**Session 16: Cellular Therapy**
08:30-09:15	*Controversy:* Drug vs. cell therapy for viral Infection
	Moderator: **Fabio Ciceri**, Italy
08:30-08:45	Pro drugs: **Per Ljungman**, Sweden
08:45-09:00	Pro cell therapies: **Catherine M. Bollard**, USA
09:00-09:15	Discussion
09:15-10:00	*Controversy:* Do we still need ex-vivo T-cell depletion for haploidentical SCT?
	Moderator: **Catherine M. Bollard**, USA
09:15-09:30	Yes: **Rupert Handgretinger**, Germany
09:30-09:45	No: **Fabio Ciceri**, Italy
09:45-10:00	Discussion
10:00-10:30	***Coffee Break***
10:30-12:45	**Session 17: Immunotherapy**
10:30-11:15	*Controversy:* How to harness optimal GvL by T-cells?
	Moderator: **Rupert Handgretinger**, Germany
10:30-10:45	By T-cell selection: **Fred Falkenburg**, The Netherlands
10:45-11:00	By T-cell engineering: **Chiara Bonini**, Italy
11:00-11:15	Discussion
11:15-12:00	*Controversy:* For preventing relapse should DLI by donor T-cell be genetically manipulated?
	Moderator: **Chiara Bonini**, Italy
11:15-11:30	Yes: **Franco Locatelli**, Italy
11:30-11:45	No: **Eduardo Olavarria**, UK
11:45-12:00	Discussion
12:00-12:45	*Controversy:* Does host immune response determine the clinical success of anti-fungal agents after allo-SCT
	Moderator: **Per Ljungman**, Sweden
12:00-12:15	Yes: **Thomas Lehrnbecher**, Germany
12:15-12:30	No: **Gerhard Behre**, Germany
12:30-12:45	Discussion